Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Lillian TugumeCollege of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala Uganda.ORCID 0000-0002-1293-1545
Fiona V CresswellCollege of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala Uganda.ORCID 0000-0002-5070-532X
Nicole W EngenDivision of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0003-1118-4194
Asmus TukundaneCollege of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala Uganda.
Sarah KimudaCollege of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala Uganda.
Timothy MugabiCollege of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala Uganda.ORCID 0009-0006-8820-288X
Suzan NamombweCollege of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala Uganda.
Enock KagimuCollege of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala Uganda.ORCID 0000-0002-0291-651X
Mable KabahubyaCollege of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala Uganda.
Jayne EllisCollege of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala Uganda.
Nathan C BahrDivision of Infectious Diseases & International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-9431-8938
David B MeyaCollege of Health Sciences, Infectious Diseases Institute, Makerere University, Kampala Uganda.ORCID 0000-0002-8854-0321
David R BoulwareDivision of Infectious Diseases & International Medicine, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-4715-0060
Funding
NPGH LEADERs YR12: OBSSR (Greenberg, Ngwafong Mukere) & NIBIB (Lee)D43TW009345 · FIC · UNIVERSITY OF WASHINGTON · PI Dibyadyuti Datta, Chandy C. John · 2017 to 2026
$15.2M
Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis.R01AI170158 · NIAID · UNIVERSITY OF MINNESOTA · PI Nathan Bahr · 2022 to 2026
$3.5M
Novel Diagnostic Development for TB Meningitis and HistoplasmosisK23NS110470 · NINDS · UNIVERSITY OF MINNESOTA · PI BAHR, NATHAN · 2019 to 2023
$1.0M
FIC NIH HHS D43 TW009345FIC NIH HHS D43TW009345Fogarty International Center of the National Institutes of Health D43TW009345NIAID NIH HHS R01 AI170158NINDS NIH HHS K23 NS110470Northern Pacific Global HealthWellcome Early Career 300088/Z/23/ZWellcome TrustWellcome Trust 203905/Z/16/Z
6 · The paper itself
Abstract
We enrolled 135 adults with tuberculous meningitis (TBM), including 83% with HIV. Participants with baseline C-reactive protein (CRP) ≥40 mg/L had 3 times higher odds of an 8-week modified Rankin scale ≥4 (adjusted odds ratio, 2.78; 95% CI: 1.28-6.04; P = .010). CRP is a viable prognostic biomarker in TBM.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Prognostic Value of C-Reactive Protein in Adults With Tuberculous Meningitis: A Prospective Cohort Study. · full record | OpenQuestion